-
Qilu pharmaceutical Shenjie leads the innovation of nerve repair drugs
Time of Update: 2014-11-05
Central nervous system injury is a common disease leading to human death and the main cause of human disability Every year, millions of new patients with central injury need to be treated in China, an
-
Apatinib, a new gastric cancer drug of Hengrui medicine, has obtained new drug certificate
Time of Update: 2014-11-04
According to reports, apatinib is mainly used in the treatment of advanced gastric cancer after the failure of standard chemotherapy It is the first small molecule anti angiogenesis targeted drug prov
-
International Forum on research and development of major innovative drugs and disease models held in Chengdu
Time of Update: 2014-11-03
The forum focused on innovative drugs and disease models in major fields such as metabolic system diseases, immune system diseases and central nervous system diseases More than 150 well-known experts
-
Paroxetine, a new depression drug of Huahai pharmaceutical, was approved by FDA
Time of Update: 2014-11-03
According to reports, the original research company of paroxetine tablets is Apotex technologies, which can be used to treat depression, obsessive-compulsive disorder, panic disorder or social anxiety
-
Lepu medical has obtained exenatide, the first generic drug of Chengdu sannuo 3 + 6 diabetes
Time of Update: 2014-10-31
According to the company's insiders, this cooperation is mainly based on technical cooperation After the approval, Chengdu shengnuo is still responsible for the production Lepu medical is responsible
-
The production of 5 new reduced glutathione enteric coated capsules and 6 generic adenosylmethionine succinate for injection in Shuanglu pharmaceutical industry was accepted
Time of Update: 2014-10-27
According to the public information, reduced glutathione enteric coated capsules have been used for injection, tablet and eye drops in China, and there is no enteric coated capsule formulation In addi
-
In the first half of this year, new drug acceptance volume of CDE reached a new high
Time of Update: 2014-10-27
Tao Jianhong said that compared with previous years, this year's growth rate is larger In the first half of 2014, the number of drugs accepted by CDE was more than 4500, up 22% compared with the same
-
Kemena is a historic turning point from imitation to creation in China
Time of Update: 2014-10-27
According to the 2013 drug review report issued by CFDA drug review center, the largest proportion of tumor drugs in clinical research, no matter the international multi center clinical trial applicat
-
Market situation of anti osteoporosis drugs in China
Time of Update: 2014-10-27
It is understood that China has become the country with the largest number of osteoporosis patients in the world, whose severity is second only to cardiovascular disease The national large-scale epide
-
Inventory of potential application enterprises of class 1.1 new drugs in the first three quarters of 2014
Time of Update: 2014-10-22
I according to the statistics of insight - China Pharma data database of DXY, in 2014, there were 134 applications for q1-q3 chemical drugs (calculated by acceptance number, the same below) involving
-
Huabang Pharmaceutical Group 1.5 skin drug tazarotene betamethasone cream entered the site for inspection this month
Time of Update: 2014-10-22
According to the public information, tazarotene betamethasone cream is a compound preparation of tazarotene and betamethasone, which is mainly used for the treatment of psoriasis It is developed by Hu
-
New drug aripiprazole of class 3.1 of Enhua pharmaceutical is undergoing three in one review, which is expected to be approved within this year
Time of Update: 2014-10-21
Aripiprazole is a new type of atypical antipsychotic drug, which was listed in China in 2004 Due to the remarkable curative effect on the positive and negative symptoms of schizophrenia, the products
-
Hengrui pharmaceutical will usher in a new drug harvest period in the next three years
Time of Update: 2014-10-21
Dai Hongbin, Secretary of the board of directors of Hengrui pharmaceutical, said that in the next three years, innovative drugs apatinib, famitinib, long-term CSF of biological innovative drugs, and a
-
The application of tegrilol, a new chemical drug of class 3.1 in Kelun Pharmaceutical Co., Ltd., has been accepted
Time of Update: 2014-10-21
Tegrilol is a new and selective small molecule anticoagulant developed by AstraZeneca to reduce cardiovascular death and heart attack in patients with acute coronary syndrome (ACS) In July 2011, it wa
-
Fasudil hydrochloride injection of HongRi Pharmaceutical Co., Ltd. entered the site for inspection this month
Time of Update: 2014-10-20
HongRi pharmaceutical securities office said that the application for fasudil hydrochloride injection is a supplementary application, mainly for process improvement to improve product quality At the s
-
Isolation of cancer cell killing virus from mosquitoes in Hainan Province by Sun Yat sen University
Time of Update: 2014-10-20
After 10 years of intensive research, a natural virus was isolated from the research group of Professor Yan Guangmei, Medical College of Zhongshan University It can selectively infect and kill a varie
-
"Wenyi Kangle small molecule new drug R & D center" to build a research platform for anti influenza small molecule drugs
Time of Update: 2014-10-18
Qu Jia, President of Wenzhou Medical University, Li Xuekun, vice president, Xu Shundong, director of the Municipal Science and Technology Bureau, Li Zuohang, director of the talent office, Bai Zhiping
-
New drug R & D strategy and R & D pipeline of domestic pharmaceutical enterprises are gradually clear
Time of Update: 2014-10-18
It is a general trend that the competition of generic drugs is becoming more and more intense from generic drugs to innovative drugs What's more, with the expiration of patent concentration, there wil
-
Palonosetron hydrochloride, a class 3.1 antiemetic of Zhejiang puluokangyu Pharmaceutical Co., Ltd., will enter the site for inspection
Time of Update: 2014-10-16
It is understood that palonosetron hydrochloride is the second generation of 5-HT3 receptor antagonist, which is mainly used in the treatment and prevention of acute nausea and vomiting caused by mode
-
Ninofloxacin malate capsule, a new drug of Zhejiang medicine, has passed the CDE expert review meeting
Time of Update: 2014-10-14
On October 13, the company confirmed that the drug had passed the expert review meeting, along with the API, "the follow-up is waiting for on-site inspection" This means that the important obstacles t
